iCAD (NASDAQ: ICAD) delivers innovative cancer detection, radiation therapy solutions, and management services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a variety of upgradeable, computer aided detection (CAD) and workflow solutions to support breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a non-invasive technology that targets cancer while decreasing exposure to surrounding healthy tissue. For more information, visit the company’s website at www.icadmed.com.